摘要
Abstract
Objective:To observe the efficacy of Sacubitril Valsartan Sodium in the treatment of patients with acute myocardial infarction and cardiac dysfunction undergoing percutaneous coronary intervention(PCI).Method:A total of 120 patients with acute myocardial infarction with cardiac insufficiency after PCI were selected from March 2021 to October 2023 in Beijing Renhe Hospital.According to the random envelope method,the control group(59 cases)received conventional treatment after surgery,and the study group(61 cases)combined with Sacubitril Valsartan Sodium.The application effect was compared between two groups.Result:The total effective rate,mean arterial pressure and left ventricular ejection fraction(LVEF)of the study group were higher than those of the control group,and left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),interventricular septal thickness(IVST),resting heart rate and the level of N terminal pro B type natriuretic peptide(NT-proBNP)were lower than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:On the basis of conventional treatment after PCI,the combined use of Sacubitril Valsartan Sodium can significantly alleviate the clinical symptoms of patients with acute myocardial infarction with cardiac insufficiency,stabilize the ventricular structure,and promote the improvement of cardiac function,and the treatment is safe and practical.关键词
经皮冠状动脉介入术/沙库巴曲缬沙坦钠/急性心肌梗死/心功能不全/心功能Key words
Percutaneous coronary intervention/Sacubitril Valsartan Sodium/Acute myocardial infarction/Cardiac insufficiency/Cardiac function
